Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2- induced contractions in canine coronary arteries

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1065-1070

  Li, Ping ^a   Ferrario, Carlos M ^a   Brosnihan, K Bridget ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; THROMBOXANE A2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DOG; DOSE RESPONSE; HYPERTENSION; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CORONARY VESSELS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LOSARTAN; MALE; MUSCLE CONTRACTION; TETRAZOLES; THROMBOXANE A2;

EID: 0030911212     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. BERLINER, J. A., NAVAB, M., FOGELMAN, A. M., FRANK, J. S., DEMER, L. L., EDWARDS, P. A., WATSON, A. D. AND LUSIS, A. J. : Atherosclerosis: Basic mechanisms (oxidation, inflammation, and genetics). Circulation 91: 2488-2496, 1995.
2. 2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J. Pharmacol. EXD. Ther. 268: 747-268, 1994.
3. BRUNNER, H. R., DELACRETAZ, E., NUSSBERGER, J., BURNIER, M. AND WAEBER, B.: Angiotensin II antagonists DuP 753 and TCV 116. J. Hypertension 12: S29-S34, 1994.
4. CACHOFEIRO, V., MAESO, R., RODRIGO, E., NAVARRO, J., RUILOPE, L. M. AND LAHERA, V.: Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 26: 236-243, 1995.
5. CHIU, A. T., McCALL, D. E., PRICE, W. A., JR., WONG, P. C., CARINI, D. J., DUNUA, J. V., WEXLEK, R. R., Yoo, S. E., JOHNSON, A. L. AND TIMMERMANS, P. B. M. W. M.: In citro pharmacology of DuP753. Am. J. Hypertension 4: 282S-287S, 1991.
6. CORRIU, C., BERNARD, S., SCHOTT, C. AND STOCLET, J.C.: Effects of losartan on contractile responses of conductance and resistance arteries from rats. J. Cardiovasc. Pharmacol. 26: 688-692, 1995.
7. DAHLOF, B.: The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J. Hypertension 11: S29-S35, 1993.
8. 2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension 19: 795-798, 1992.
9. DEGRAAEF, G. L., PALS, D. T., COUCH, S. J. AND LAWSON, J. A.: Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in nonhuman primates. J. Pharmacol. Exp. Ther. 264: 6-10, 1993.
10. DOSTAL, D. E. AND BAKER, K. M.: Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT receptor. Am. J. Hypertension 5: 276-280, 1992.
11. FERRARIO, C. M., MORIGUCHI A. AND BROSNIHAN, K. B.: Angiotensin mechanisms in hypertension. In Handbook of Hypertension, ed. by D. Ganten and W. De Jong, pp. 441-461, Elsevier Science, New York. 1994.
12. JAISWAL, N., DIZ, D. I., TALLANT, E. A., KHOSLA, M. C. AND FERRARIO, C. M.: The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin release. Am. J. Hypertension 4: 228-233, 1991.
13. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 15: 475-481, 1990.
14. KONIECZKOWSKI, M., DUNN, M. J., STORK, J. E. AND HASSID, A.: Glomerular synthesis of prostaglandins and thromboxane in spontaneously hypertensive rats. Hypertension 5: 446-452, 1983.
15. LI, Z., BOSCH, S. M., SMITH, T. L. AND DIZ, D. I.: Interactions of non-peptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. J. Cardiovasc. Pharmacol. 28: 425-431, 1996.
16. 2-mediated mechanism of vascular contraction in hypertensive rats: Relation to lipoxygenase and prostacyclin synthase activities. Circ. Res. 74: 197-205, 1994.
17. LIN, L., MISTRY, M., STIER, C. T., JR. AND NASJLETTI, A.: Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension 17: 517-525, 1991.
18. 2 (TP) receptors. Prostaglandins 44: 89-99. 1992.
19. LIU, Y. J.: Antagonist effect of Losartan on angiotensin II induced contraction in five isolated smooth muscle assays. Eur. J Pharmacol. 240: 147-154, 1993.
20. MAESO, R., NAVARRO, J., MUNOZ-GARCIA, R., RODRIGO, E., RUILOPE, L. M., LAHERA, V. AND CACHOFEIRO, V.: Losartan but not captopril reduces catecholamme constrictor response in aortic rings from SHR. Hypertension 25: 521995.(Abstract)
21. MISTRY, M. AND NASJLETTI, A.: Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension 11: 758-762, 1988.
22. MORIGUCHI, A., BROSNIHAN, K. B., KUMAGAI, H., GANTEN, D. AND FERRARIO, C. M.: Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am. J. Physiol. 266: R1273-R1278, 1994.
23. MUNAFO, A., CHRISTEN, Y., NUSSBERGER, J., SHUM, L. Y., BORLAND, R. M., LEE, R. J., WAEBER, B., BIOLLAZ, J. AND BRUNNER, J. R.: Drug concentration response relationships in normal volunteers after oral administration of losartan. an angiotensin II receptor antagonist. Clin Pharmacol Ther 51: 513-521, 1992.
24. OGLETREE, M. L., HARRIS, D. N., GREENBERG, R., HASLANGER, M. F. AND NAKANE, M.: Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234: 435-441, 1985.
25. OHLSTEIN, E. H., GELLAI, M., BROOKS, D. P., VICKERY, L., JUGUS, J., SULPIZUIO, A., RUFFOLO, R. R., JR., WEINSTOCK, J. AND EDWARDS, R. M.: The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J. Pharmacol. Exp. Ther. 262: 595-601, 1992.
26. PALS, D. T., MASUCCI, F. D., DENNING, G. S., JR., SIPOS, F. AND FESSLER, D. C.: Role of the pressor action of angiotensin II in experimental hypertension. Circ. Res. 29: 673-681, 1971.
27. PETTINGER, W. A., KEETON, K. AND TANAKA, K.: Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. Clin. Pharmacol. Ther. 17: 146-158, 1975.
28. 3 receptors in the conscious rat. Br. J. Pharmacol. 114: 1563-1570, 1995.
29. RHALEB, N. E., ROUISSI, N., NANTEL, F., D'ORLEANS-JUSTE, P. AND REGOLI, D.: DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 17: 480-484, 1991.
30. SACHINIDIS, A., Ko, Y., WEISSER, P., MEYER ZU BRICKWEDDE, M.K., DUSING. R., CHRISTIAN, R., WIECZOREK, A. J. AND VETTER, H.: EXP3174, a metabolite of losartan (MK954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertension 11: 155-162, 1993.
31. SWEET, C. S., GROSS, D. M., ARBEGAST, P. T., GAUL, S. L., BRITT, P. M., LUDDEN, C. T., WEITZ, D. AND STONE, C. A.: Antihypertensive activity of N-((S)-1-(Ethoxycarbonyl)-3-PhenylpropL)-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J. Pharmacol. Exp. Ther. 216: 558-566, 1981.
32. TALLANT, E. A. AND FERRARIO, C. M.: Drug evaluation: Cardiovascular & renal: Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp. Opin. Invest. Drugs 5: 1-14, 1996.
33. TIMMERMANS, P. B. M. W. M., WONG, P. C., CHIU, A. T., HERBLIN, W. F., BENFIELD, P., CARINI, D. J., LEE. R. J., WEXLER, R. R., SAYE, J. M. AND SMITH, R. D.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251, 1993.
34. TIMMERMANS, P. B. W. M.. WONG, P. C., CHIU, A. T. AND SMITH, R. D. The preclinical basis of the therapeutic evaluation of losartan. J. Hypertension 13: S1-S13, 1995.
35. 1-receptor antagonist losartan in hypertension. J. New Dev. Clin. Med. 13: 195-206, 1996.
36. WONC, P. C., PRICE, W. A., CHIU, A. T., DUNCIA, J. V., CARINI, D. J., WEXLER, R. R., JOHNSON, A. L. AND TIMMERMANS, P. B. M. W. M.: Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 252: 719-725, 1990a.
37. WONG, P. C., PRICE, W. A., JR., CHIU, A. T., DUNCIA, J. V., CARINI, D. J., WEXLER, R. R., JOHNSON, A. L. AND TIMMERMANS, P. B. M. W. M.: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, and orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255: 211-217, 1990b.
38. WONG, P. C., PRICE, W. A. J., CHIU, A. T., DUNCIA, J. V., CARINI, D. J., WEXLER, R. R., JOHNSON, A. L. AND TIMMERMANS, P. B. M. W. M.: Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 15: 459-468, 1990c.